2. Stem Cell/Wnt
  3. Organoid Wnt
  4. IWR-1

IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

IWR-1

IWR-1 構造式

CAS 番号 : 1127442-82-3

容量 在庫状況
50 mg   お問い合わせ  
100 mg   お問い合わせ  
250 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

IWR-1 関連抗体

Top Publications Citing Use of Products

Wnt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis[1][2][4].

Cellular Effect
Cell Line Type Value Description References
A549 GI50
>100 μM
Compound: IWR1
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
[PMID: 24950489]
HEK293 IC50
136 μM
Compound: 1, IWR1
Inhibition of Tankyrase in human HEK293 cells assessed as inhibition of Wnt pathway by Wnt3a-induced STF assay
Inhibition of Tankyrase in human HEK293 cells assessed as inhibition of Wnt pathway by Wnt3a-induced STF assay
[PMID: 23316926]
HEK-293T IC50
26 nM
Compound: 1, IWR-1
Inhibition of beta-casein-dependent canonical Wnt3 pathway in human HEK293T cells by luciferase reporter gene assay
Inhibition of beta-casein-dependent canonical Wnt3 pathway in human HEK293T cells by luciferase reporter gene assay
[PMID: 22191557]
HepG2 GI50
95.4 μM
Compound: IWR1
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 24950489]
HT-29 GI50
>100 μM
Compound: IWR1
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 24950489]
HT-29 IC50
24.4 μM
Compound: IWR1
Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control
Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control
[PMID: 24950489]
HT-29 IC50
9.52 μM
Compound: IWR-1
Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method
Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method
[PMID: 34062253]
LoVo GI50
63.1 μM
Compound: IWR1
Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay
[PMID: 24950489]
SW480 EC50
2.5 μM
Compound: 1, IWR1
Inhibition of tankyrase in human SW480 cells assessed as accumulation of axin2 after 24 hrs by Hoechst dye-based method
Inhibition of tankyrase in human SW480 cells assessed as accumulation of axin2 after 24 hrs by Hoechst dye-based method
[PMID: 23701517]
SW480 IC50
0.25 μM
Compound: 1, IWR1
Inhibition of tankyrase in human SW480 cells assessed as degradation of beta catenin after 40 to 48 hrs
Inhibition of tankyrase in human SW480 cells assessed as degradation of beta catenin after 40 to 48 hrs
[PMID: 23701517]
体外実験

IWR-1 (GMP) is cytotoxic for osteosarcoma cancer stem-like cells (CSCs)[1].
IWR-1 (GMP) suppresses cell migration, invasion, and matrix metalloproteinase activities of colorectal cancer cell lines[2].
IWR-1 (GMP) (2.5-10 μM, 48-96 h) is effective in reducing spheres’ viability in a concentration- and time- dependent manner in parental and spheres from MG-63 and MNNG-HOS cell lines[1].
IWR-1 (GMP) (10 μM, 96 h) increases the number of TUNEL-positive cells, reaching 4.65- and 15.83-fold differences relative to control at 96 h and promoted the activation of caspases 3/7 reaching 2.15- and 1.27-fold in MG-63 and MNNG-HOS spheres[1].
IWR-1 (GMP) (10 μM, 48 h) induces a cell cycle arrest in the G2/M phase in spheres derived from MG-63 and MNNG-HOS cell lines and increases the percentage of cells in the S phase slightly[1].
IWR-1 (GMP) (10 μM, 48 h) inhibits secondary sphere-forming efficacy by approximately 53% and 55% of the first-generation 7-day old spheres in MG-6t4 and MNNG-HOS cells[1].
IWR-1 (GMP) (5-50 μM, 24-48 h) decreases the proliferation of HCT116 cells in a dose- and time-dependent manner[2].
IWR-1 (GMP) (5-50 μM, 24-48 h) inhibits TNF-α-stimulated migration in HCT116 and HT29 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IWR-1 関連抗体

Cell Viability Assay[1]

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 2.5, 5, 7.5, 10 μM
Incubation Time: 48 and 96 h
Result: Reduced cell viability when concentration is higher than 5 μM.
Elicited more than 70% reduction of cell viability in spheres derived from the two cell lines at 96 h with 10 μM.
Had minimal effect on parental cells since the Wnt/β-catenin signaling is absent in these cells. Increased the susceptibility of spheres towards Doxorubicin (HY-15142) when treated in combination with increasing concentrations of Doxorubicin (0.01-100 μM).

Western Blot Analysis[1]

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Led to an upregulation of Bak and a downregulation of Bcl-2 (key proteins involved in mitochondrial-dependent apoptosis), which contributes to a Bak/Bcl-2 ratio >1 that prone the cells to undergo apoptosis.

RT-PCR[1]

Cell Line: MG-63 and MNNG-HOS spheres and parent cells
Concentration: 10 μM
Incubation Time: 96 h
Result: Led to an upregulation of Bak and a downregulation of Bcl-2 (key proteins involved in mitochondrial-dependent apoptosis), which contributes to a Bak/Bcl-2 ratio >1 that prone the cells to undergo apoptosis.
Results in a higher β-catenin nuclear/cytoplasmic ratio in spheres, indicating an increased Wnt/β-catenin pathway activation in osteosarcoma spheres.
Stabilized Axin2 protein levels.
Diminished the protein expression levels of Cyclin D1 in both parental cells and spheres.

Western Blot Analysis[2]

Cell Line: HCT116 cells
Concentration: 5, 10, 20, 50 μM
Incubation Time: 0, 4, 8, 24, 48 h
Result: Increased the levels of the epithelial marker E-cadherin whilst decreased the mesenchymal markers N-cadherin, Vimentin, and Snail dose- and time-dependently.
Inhibited the EMT process in HCT116 cells effectively.
Decreased β-catenin expression and inhibited the EMT-like expressional changes whereby decreasing N-cadherin and Snail and increasing E-cadherin expressions, even in the presence of TNF-α (HY-P1860) (10 ng/mL for 24 h)-induced EMT stimulation.
Decreased the phosphorylation of Akt in a concentration- and time-dependent manner.
Decreased the surviving expression in a concentration- and time-dependent manner, thereby promoting tumor proliferation directly or indirectly through regulating cancer cell homeostasis.
Reduced MMP activities only when surviving was suppressed.
体内実験

IWR-1 (5 mg/kg, intratumorally, each 2 d for 12 d) induces a marked inhibition of tumor growth in osteosarcoma mouse model[1].
IWR-1 (GMP) (10 mg/kg, s.c., on days 1, 3, 5) ameliorates IL-36γ (2 μg/mouse on days 1, 3, 5)-mediated exacerbation of psoriatic skin lesions in an Imiquimod (IMQ) (HY-B0180)-induced psoriasis-like mice model[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Immunocompromised nude mice (6-week old female Swiss nude) were injected sub-cutaneously the pGL4-transfected MNNG-HOS cells (2×106 cells/100 mL PBS)[1]
Dosage: 5 mg/kg
Administration: Intratumorally, each 2 d for 12 d
Result: Resulted in slower tumor growth rate and reduction in tumor size by 73% and 71% in comparison to control and to Doxorubicin-treated (8 mg/kg, i.p., each 4 d for 12 d) groups.
Enhanced the therapeutic efficacy of Doxorubicin shown by a greater reduction of tumor burden at the end of the treatment in opposite to Doxorubicin alone.
Animal Model: Balb/c mice (aged 6-8 weeks) with shaven back and treated with a daily topical dose of IMQ cream[3]
Dosage: 10 mg/kg
Administration: Subcutaneous injection (s.c.) on days 1, 3, 5
Result: Increased epidermal thickening with keratinocyte thickness.
Significantly diminished the effect of IMQ on hyperplasia in the IMQ+IWR-1 group.
Ameliorated the pathological changes in IL-36γ-induced psoriasiform skin lesion.
Reversed IL-36γ-mediated upregulation of inflammatory factors (IL-17 A and IFN-γ) in psoriatic lesions.
Reversed IL-36γ-mediated upregulation of β-catenin and DKK1 expression.
分子量

409.44

分子式

C25H19N3O3
CAS 番号
SMILES

O=C(NC1=C2N=CC=CC2=CC=C1)C3=CC=C(N(C([C@]4([H])[C@](C5)([H])C=C[C@]5([H])[C@]64[H])=O)C6=O)C=C3
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IWR-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IWR-1 (GMP)1127442-82-3endo-IWR 1 (GMP)IWR-1-endo (GMP)OrganoidWntInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
IWR-1
製品番号:
HY-12238G
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.